Cancer immunotherapy using checkpoint blockade
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...
Publications
4 shownPembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Frequent Co-Authors
Researcher Info
- h-index
- 4
- Publications
- 4
- Citations
- 15,135
- Institution
- Parker Institute for Cancer Immunotherapy
External Links
Identifiers
- ORCID
- 0000-0003-3669-8458
Impact Metrics
h-index
4
h-index: Number of publications with at least h citations each.